What is Triptorelin (GnRH)
 
Decapeptide Triptorelin ((D-Trp6)-GnRH)) acts as an agonist analog of endogenous peptide hormone Gonadotropin-releasing hormone (GnRH), thus reversibly repressing of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). It is a potent GnRH receptor agonist. After chronic, continuous administration, Triptorelin effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men. It was patented in 1975 and approved for medical use in 1986. Animal studies comparing triptorelin to native GnRH found that triptorelin had 13 fold higher releasing activity for luteinizing hormone, and 21-fold higher releasing activity for follicle-stimulating hormone.
 
 
Triptorelin (GnRH) Benefits:
 
Treatment for prostate cancer (PCa) as part of androgen deprivation therapy (ADT)
Use in reproduction medicine, endometriosis, central precocious puberty